Unique ID issued by UMIN | UMIN000007806 |
---|---|
Receipt number | R000009195 |
Scientific Title | The feasibility study of accelated infliximab infusion during maintenance phase |
Date of disclosure of the study information | 2012/05/01 |
Last modified on | 2018/10/06 07:55:21 |
The feasibility study of accelated infliximab infusion during maintenance phase
The feasibility study of accelated infliximab infusion during maintenance phase
The feasibility study of accelated infliximab infusion during maintenance phase
The feasibility study of accelated infliximab infusion during maintenance phase
Japan |
patient in whom infliximab is indicated(rheumatoid arthritis, Crohn's disease, Ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis)
Medicine in general | Gastroenterology | Hematology and clinical oncology |
Clinical immunology | Dermatology | Orthopedics |
Others
NO
To evaluate feasibility of accelated infliximab infusion in the maintenance treatment
Safety
Exploratory
Pragmatic
Phase II
The incidence of infusion reaction with 60min infliximab accelated infusion
1) patients preference
2) discontinuous rate due to infusion reaction
3) success rate of rescue by usual 2hrs infusion after occurrence of infusion reaction
4) evaluation of premedication
Interventional
Single arm
Non-randomized
Open -but assessor(s) are blinded
Uncontrolled
1
Treatment
Medicine | Other |
Administration of intravenous infliximab infusion with 60 min accelated procedure for patients who are already successfully treated with usual 2hr infuion without infusion reaction. The tolerable patient continue to receive more five treatment with 60min procedure.
Not applicable |
Not applicable |
Male and Female
1)infliximab-maintenance treatment adequate case, who are already successfully administrated with usual 2hr infuion without infusion reaction at three and more initial treatment.
2)Adequate organ fanction, no hematological disorder
3)Written informed consent
1)active serious infection
2)active tuberuculosis infection
3)past history of bronchial asthma
4)past history of hypersensitivity reaction and/or allergy for any drugs and food
5)allergy and/or hypersensitivity for mouse-derived protein
6)demyelinating disease(MS)
7)congestive heart failure
8)pregnant, nursing or likelihood of pregnancy woman
9)unable to birth control during and after 6 months from the latest infliximab administration
10)past treatment history with infliximab and readministration at an interval of over three months
11)Not suitable for participating in the study for any other reason
54
1st name | |
Middle name | |
Last name | Yuichi Takiguchi |
Graduate School of Medicine, Chiba University
Department of Medical Oncology
1-8-1, Inohana, Chuo-ku, Chiba
043-222-7171
1st name | |
Middle name | |
Last name | Emiko Sakaida |
Graduate School of Medicine, Chiba University
Department of Medical Oncology
1-8-1, Inohana, Chuo-ku, Chiba
043-222-7171
esakaida@faculty.chiba-u.jp
Chiba University Hospital
None
Self funding
NO
千葉大学医学部附属病院 Chiba University Hospital
2012 | Year | 05 | Month | 01 | Day |
Partially published
Completed
2012 | Year | 02 | Month | 28 | Day |
2012 | Year | 06 | Month | 01 | Day |
2014 | Year | 12 | Month | 01 | Day |
2014 | Year | 12 | Month | 01 | Day |
2014 | Year | 12 | Month | 01 | Day |
2015 | Year | 03 | Month | 01 | Day |
2012 | Year | 04 | Month | 21 | Day |
2018 | Year | 10 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009195